+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 1
Phase 2
Age: 18Years - 75Years
MALE
ID06325709

Gene Therapy Using Base-Edited Hematopoietic Stem Cells for X-Linked Chronic Granulomatous Disease Safety and Efficacy Evaluation

Led by National Institute of Allergy and Infectious Diseases (NIAID) · Updated on 2026-11-03

15

Participants Needed

1

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

Researchers are investigating a gene therapy approach using base-edited autologous hematopoietic stem and progenitor cells HSPCs to treat males aged 18 to 75 with X-linked Chronic Granulomatous Disease X-CGD, a rare immune disorder caused by mutations in the CYBB gene. The study aims to evaluate the safety and effectiveness of this single infusion treatment in improving white blood cell function and reducing infections related to CGD. Participants will first undergo stem cell collection through apheresis during the development phase. In the treatment phase, they will receive Campath alemtuzumab to reduce immune response risk, followed by chemotherapy with busulfan to condition the body for the infusion of the base-edited stem cells. They will also take sirolimus for 3 to 6 months to further prevent immune reactions. Additional medications like Palifermin, Filgrastim, and Plerixafor are used to support the treatment process. Throughout the study, participants will have follow-up visits at months 3, 6, 12, 18, 24, and yearly up to 5 years, with continued monitoring up to 15 years under a separate protocol. Assessments include safety checks, blood tests for gene repair and immune function, DNA sequencing for gene editing accuracy, and tracking clinical benefits such as infection rates. The study measures both short-term and long-term effects of the gene therapy.

CONDITIONS

Brief Title

Base Editing for Mutation Repair in Hematopoietic Stem & Progenitor Cells for X-Linked Chronic Granulomatous Disease

Research Team

S

Suk S De Ravin, M.D.

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here